Observational study in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Joseph Hunter HolthoffDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.ORCID 0000-0002-7098-7811
Nithin KarakalaDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Alexei G BasnakianDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.ORCID 0000-0002-9115-6283
Ricky D EdmondsonDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Todd Wesley FiteSection of Nephrology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States.
Neriman GokdenDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Yanping HarvilleDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Christian HerzogDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.ORCID 0000-0001-6024-3491
Kaegan G HolthoffDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Luis A JuncosDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.ORCID 0000-0002-4630-2747
Katlyn L ReynoldsDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Randall S SheltonSection of Nephrology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States.
John M ArthurDepartment of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.ORCID 0000-0003-4342-4762
Funding
Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
The Role o f Tetrahydrobiopterin (BH4) Bioavailability in Radiation-induced Skin InjuryP20GM109005 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN · 2015 to 2024
$21.1M
Institutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3M
CTSA K12 Program at the University of Arkansas for Medical SciencesK12TR004924 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI Jason Eli Farrar, Joshua Kennedy · 2024 to 2026
$2.3M
Prognostic markers in postoperative acute kidney injuryR01DK080234 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ARTHUR, JOHN M. · 2008 to 2011
$1.5M
Biomarkers of Early Renal Functional Decline in Type 2 DiabetesR01DK101034 · NIDDK · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M. · 2014 to 2017
$1.2M
BLRD VA I01 BX002425BLRD VA IK6 BX006184Dialysis Clinics (DCI) DCI RF#C-4208HHS | National Institutes of Health (NIH) 5P20GM109005HHS | National Institutes of Health (NIH) KL2TR003108HHS | National Institutes of Health (NIH) P20GM109005-06HHS | National Institutes of Health (NIH) R01DK080234HHS | National Institutes of Health (NIH) R01DK101034HHS | National Institutes of Health (NIH) UL1TR003107NCATS NIH HHS K12 TR004924NCATS NIH HHS KL2 TR003108NCATS NIH HHS UL1 TR003107NIDDK NIH HHS R01 DK080234NIDDK NIH HHS R01 DK101034NIGMS NIH HHS P20 GM109005U.S. Department of Veterans Affairs (VA) 2I01BX002425
6 · The paper itself
Abstract
The ability to predict progression to severe acute kidney injury (AKI) remains an unmet challenge. Contributing to the inability to predict the course of AKI is a void of understanding of the pathophysiological mechanisms of AKI. The identification of novel prognostic biomarkers could both predict patient outcomes and unravel the molecular mechanisms of AKI. We performed a multicenter retrospective observational study from a cohort of patients following cardiac surgery. We identified novel urinary prognostic biomarkers of severe AKI among subjects with early AKI. Of 2,065 proteins identified in the discovery cohort, insulin-like growth factor binding protein 1 (IGFBP-1) was the most promising. We validated IGFBP-1 as a prognostic biomarker of AKI in 213 patients. In addition, we investigated its role in the pathophysiology of AKI using a murine model of cisplatin-induced AKI (CIAKI). Urinary IGFBP-1 concentration in samples collected from patients with stage 1 AKI following cardiothoracic surgery was significantly higher in patients who progressed to severe AKI compared with patients who did not progress beyond stage 1 AKI (40.28 ng/ml vs. 2.8 ng/ml,
Indexed as
Acute Kidney InjuryInsulin-Like Growth Factor Binding Protein 1KidneyAgedAnimalsBiomarkersCardiac Surgical ProceduresCisplatinDisease Models, AnimalDisease ProgressionFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutBiomarkersCisplatinIGFBP1 protein, humanInsulin-Like Growth Factor Binding Protein 1acute kidney injurybiomarkerIGFBP-1insulin-like growth factor binding protein 1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury. · full record | OpenQuestion